{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-009540","form_type":"8-K/A","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2023-01-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.084885+00:00","generated_at":"2026-06-20T14:46:31.760886+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ARS Pharma files merger financials: 2021 revenue $5.5M, net loss $20.2M","bullets":["Audited 2021 revenue $5.5M vs $17.8M in 2020; net loss $20.2M vs $1.1M.","Cash $60.1M at Dec 31, 2021; accumulated deficit $42.3M; expects continued losses.","Product candidate ARS-1 (Neffy) for needle-free epinephrine in anaphylaxis.","Merger with Silverback closed Nov 2022; this amendment provides previously missing financials.","Pro forma combined financials filed as Exhibit 99.3; shows combined entity post-merger."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-009540","json":"https://secwatch.observer/filing/0001193125-23-009540.json","markdown":"https://secwatch.observer/filing/0001193125-23-009540.md","text":"https://secwatch.observer/filing/0001193125-23-009540.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000119312523009540/0001193125-23-009540-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000119312523009540/d448105d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T14:46:31.760886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}